In Ireland, Nuritas, an AI-powered peptide discovery firm, has successfully closed an oversubscribed $42 million Series C funding round. The round was led by M&G Investments with participation from McWin Capital Partners, Grosvenor and ECBF. U2 rockers Bono and The Edge were among Nuritas’ early investors.
Nuritas aims to bring to market previously inaccessible health-promoting peptide ingredients discovered in various food plant sources. Its AI platform, Magnifier™, identifies peptides 10-50 times faster than traditional methods, with an industry-leading clinical success rate of over 80%, far exceeding industry standards of low single digits.
The $42 million funding will enable Nuritas to scale its operations, expand its global customer base, and reach more consumers worldwide. The company recently launched PeptiYouth™, a peptide that reduces wrinkle depth by promoting collagen production. This ingredient is now featured in skin-care products in the U.S. and Asia. Nuritas also plans to introduce three new clinically validated peptide ingredients in 2025.